Acute Effects of Leg Heating on Skeletal Muscle Blood Flow

NCT ID: NCT03763357

Last Updated: 2023-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to apply local heat to the legs, thighs and buttocks of patients with peripheral arterial disease and use PET/CT imaging with an injectable stable radiotracer to study direct measurement of blood flow in the legs pre and post heat treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cilostazol is the only effective medication available to treat walking pain (intermittent claudication) and it has multiple side effects. Overall improvement in walking performance in patients who use cilostazol is small. Endovascular and surgical interventions are effective alternatives for patients who don't respond to medical therapy, however, these procedures are costly and only applicable to patients with certain lesions types and carry a high risk of restenosis.

Heat therapy (HT) is an emerging non-invasive approach that has been shown to enhance vascular function of the leg in old individuals. The objective of this study is to test the hypothesis that a single session of heat therapy will increase local muscle tissue blood flow in the calf of patients with PAD as assessed by PET/CT imaging of generator-based 62Cu-ETS.

Subjects who have met inclusion criteria will volunteer for a single experimental visit. Participants will wear the water circulating pants and asked to rest supine for 30 minutes inside the scanner. Water at 43 degrees C will be perfused through the pants for 90 minutes with the goal to increase skin temperature in the calf to 39 degrees C. IV injections of 62Cu-ETS and subsequent perfusion imaging will be performed at the end of the 30 minute baseline period, after 45 minutes of heat therapy and at the end of the intervention (90 minutes). Due to the short half life of 62Cu, radioactivity from the prior administrations will not interfere with acquisition of a subsequent PET scan at this timing interval.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All of the subjects in this study will receive leg heat therapy.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heat Therapy

Subject will dress in water-circulating trousers that are connected to a Heat Therapy (HT) pump. Warm water (42-43 degrees C) will be perfused through the pants for 90 minutes.

Group Type EXPERIMENTAL

Heat Therapy (HT)

Intervention Type DEVICE

Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Heat Therapy (HT)

Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women with a stable symptomatic claudication for \>/= 6 months
* Ankle brachial index \< 0.9

Exclusion Criteria

* Uncontrolled diabetes
* Heart failure
* COPD
* Critical limb ischemia
* Prior amputation
* Exercise-limiting co-morbidity
* Recent (\< 3 months) intra-inguinal revascularization or planned in study period
* Plans to change medical therapy during duration of study
* Active cancer
* Chronic kidney disease (eGFR \< 30)
* HIV positive, active HBV or HCV disease
* Presence of an clinical condition that makes the patient not suitable to participate in the trial
* Peripheral neuropathy, numbness or paresthesia in the legs
* Morbid obesity BMI \> 36 or unable to fit into water-circulating pants
* Open wounds or ulcers on the extremity
* Claustrophobia/unable to tolerate PET/CT scanning
* Women of child-bearing age
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Roseguini, Bruno, PhD

INDIV

Sponsor Role collaborator

Purdue University

OTHER

Sponsor Role collaborator

Indiana University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Raghu Motaganahalli

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Raghu L Motaanahalli, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1809400414

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Microvascular Blood Flow During Passive Heating
NCT06565221 NOT_YET_RECRUITING NA
Heat Therapy and Peripheral Artery Disease
NCT06827691 NOT_YET_RECRUITING NA
Leg Heat Therapy in Elderly Individuals
NCT05543980 COMPLETED PHASE1
Radial Artery Vasodilation Heat Study
NCT03620383 COMPLETED PHASE1/PHASE2
Heat Therapy in Type 2 Diabetes
NCT06596967 RECRUITING PHASE1